<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C0D1CA6E-1770-4AA4-9EC0-55336CC1D676"><gtr:id>C0D1CA6E-1770-4AA4-9EC0-55336CC1D676</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:surname>Dore</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/221B9401-2B55-43D2-BB9A-8AA7A3B7859B"><gtr:id>221B9401-2B55-43D2-BB9A-8AA7A3B7859B</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Meredith</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122870183"><gtr:id>8DA763F7-DF19-485C-8976-29A93F84E29C</gtr:id><gtr:title>Clinical Trials in Transfusion Medicine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122870183</gtr:grantReference><gtr:abstractText>This programme aims to improve current practice in transfusion medicine.|TOPPS|This RCT compares prophylactic vs no prophylactic platelet transfusions and aims to demonstrate that a policy of giving transfusions therapeutically is as clinically effective &amp;amp; safe transfusing prophylactically.|TAPS |This RCT compares pre-operative transfusion vs no transfusion in sickle cell patients undergoing low/medium risk elective surgery &amp;amp; aims to demonstrate that patients who do not have a top-up blood transfusion before an operation, recover just as well as patients who do have a transfusion. |PPIP |This trial aims to corroborate evidence from laboratory studies and show that 7 day platelets (suspended in plasma as well as an alternative suspension) function as well as 5 day platelets.|PRISM|These studies aim to test a blood filter that will remove the prions (proteins) thought to cause vCJD and ensure that the filtered blood is safe when transfused into cardiac surgery patients as well as patients who may require multiple transfusions.|GIN|This non-randomized pilot study aims to assess how safe and effective a new pooled NBS granulocyte product is at preventing and treating sepsis in 30 haemato-oncology patients.</gtr:abstractText><gtr:technicalSummary>The aim of the programme of clinical studies in transfusion medicine is to improve evidence base for safe and appropriate use of blood, blood components and alternatives to blood in order to reduce unnecessary exposure to hazards of transfusion, underpin blood service planning for blood component provision, and make best use of a scare donated resource. It is a collaboration between the MRC Clinical Trials Unit and NHS Blood and Transplant, a Special Health Authority with the remit to provide a reliable, efficient supply of blood, organs and associated services to the NHS.|Summary of Studies Currently Open to Recruitment:|TOPPS - Trial of Prophylactic Platelets |Platelet transfusions are given prophylactically to reduce the risk of bleeding in thrombocytopenia. This RCT compares prophylactic vs no prophylactic platelet transfusions in patients with haematological malignancies, &amp;amp; aims to demonstrate that a policy of not giving prophylactic transfusions is not inferior to the standard prophylactic policy, with respect to the proportion of patients developing moderate or severe bleeding.|TAPS - Transfusion Alternatives Pre-operatively in Sickle cell disease |Currently, people with Sickle-cell disease are routinely given a top-up blood transfusion before they undergo surgery in the belief that this helps recovery. However, there is no evidence that this practice is of benefit. This RCT aims to compares pre-operative transfusion vs no transfusion in sickle cell patients undergoing low/medium risk elective surgery. The total number of patients (from the UK and the US) to be recruited to this trial is approximately 400. |PPIP - Platelet Process Improvement Project |The current shelf-life of platelets is 5 days and this short shelf life can cause difficulties with stock control and availability of platelets. As long as no bacterial contamination can be identified, platelet packs can be kept for 7 days. Evidence from laboratory studies show that 7 day platelets function adequately. This trial aims to show that this result is corroborated when platelets are transfused to prevent and treat haemorrhage in thrombocytopenic patients. |PRISM - Trial of Prion-Filtered vs. Standard Red cells in Surgical and Multi-transfused patients |Study A: A non-randomised controlled trial aims to assess the safety of blood that has been passed through a filter to reduce prions (proteins) thought to cause vCJD. |Study B: This double blind RCT that will test the safety of filtered blood in 340 haematology/oncology patients who require regular transfusions for their medical care.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>966147</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Blood and Transplant (NHSBT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC/NHSBT Clinical Studies Unit</gtr:description><gtr:id>5E1DAE05-734F-47C3-91C8-DEDEEE39CB73</gtr:id><gtr:impact>This collaboration was part of the Division without Portfolio (DWP) programme to support the development of clinical trial expertise and infrastructure in areas in which there was a clinical/public health need. 

Since 2001, 10 clinical studies have been successfully completed and published in peer reviewed journals.
Disciplines involved have included transfusion medicine, epidemiology, biostatistics, data management, trial management.
A very important outcome of the collaboration is that it led to the establishment of an independent NHS BT Clinical Trials Unit (see http://www.nhsbt.nhs.uk/clinicaltrialsunit) .</gtr:impact><gtr:outcomeId>HwcXi6ZAru9-1</gtr:outcomeId><gtr:partnerContribution>NHSBT provided expertise in blood transfusion and the clinical questions together with resources to conduct the studies.</gtr:partnerContribution><gtr:piContribution>The MRC CTU provided expertise in trial design, conduct, data management and analysis to assist NHSBT to develop a programme of clinical trials and related research in transfusion medicine with the aim of improving the evidence base for blood transfusion. In addition to providing the methodological input as well as biostatistians and database management for the studies, the MRC CTU mentored NHSBT staff across all the disciplines involved in the collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient group involvement (Membership of TAPS TSC)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7F2DF2F9-7B3F-4868-97E9-F74ED0A64E07</gtr:id><gtr:impact>Annual Trial Steering Committee (TSC) meetings, regular study updates in the Sickle Cell society's newsletter.


Patient perspectives were included in the design and conduct of the trial.
Patients were made aware of this study and kept updated with the study progress.
The trial results were disseminated in this patient group.</gtr:impact><gtr:outcomeId>R2GdRZpzcd3</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Representative (TSC Membership - HLA Epitope)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>69A0EB06-2FFA-455D-A8B0-FC585A56D4EA</gtr:id><gtr:impact>Patient Representative is involved as a member of the HLA Epitope TSC. Feedback from Patient Representative on protocol and patient information was used to clarify these documents for future patients.</gtr:impact><gtr:outcomeId>gfXNzM8EfMM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>288724</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHS Blood and Transplant Research and Development (TAPS)</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>NHS Blood and Transplant (NHSBT)</gtr:fundingOrg><gtr:id>5E9EB983-AAF9-4C42-9B60-8B8EB323B071</gtr:id><gtr:outcomeId>eMSgnQkByiv0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>352659</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHS Blood and Transplant Research and Development (HLA-Epitope)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>NHS Blood and Transplant (NHSBT)</gtr:fundingOrg><gtr:id>04BD6012-198A-4554-99A4-140B60714D44</gtr:id><gtr:outcomeId>WfdQh1RGHsY0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>186035</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHS Blood and Transplant Research and Development (TRIGGER)</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>NHS Blood and Transplant (NHSBT)</gtr:fundingOrg><gtr:id>D30AECAE-8D20-47D3-8750-B01319F1B00D</gtr:id><gtr:outcomeId>SmwiEG5T8Eg</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1999999</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Blood Service (PRISM)</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Department of Health (DH)</gtr:fundingOrg><gtr:id>46E0AC15-1C99-4077-823D-C46D814E17F7</gtr:id><gtr:outcomeId>UXR2jgP5AJ4</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1999540</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>NIHR HTA Programme Grant</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>475F5071-2443-4488-B5C5-8993B49A1402</gtr:id><gtr:outcomeId>28FA4C974D50</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>367897</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHS Blood and Transplant Research and Development (TOPPS)</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>NHS Blood and Transplant (NHSBT)</gtr:fundingOrg><gtr:id>85C17F1A-A536-4270-AE0B-7A5FE5EDA103</gtr:id><gtr:outcomeId>f7b9MsqufkX0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>155639</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHS Blood and Transplant Research and Development (Planet 2)</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>NHS Blood and Transplant (NHSBT)</gtr:fundingOrg><gtr:id>860DB898-C91B-466F-8F4D-808008802472</gtr:id><gtr:outcomeId>HChpjLnZJPh0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>177751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NHS Blood and Transplant Research and Development (PROMPT)</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>NHS Blood and Transplant (NHSBT)</gtr:fundingOrg><gtr:id>DE037EA4-E897-45FD-9EF8-10280EA6EBE1</gtr:id><gtr:outcomeId>FqHeGVQXYnL0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>(EASTR) National transfusion policy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4DE29E9E-FB8B-492F-B5FF-BA89B201C70F</gtr:id><gtr:impact>Data on the survival of recipients and donor exposure rates from the EASTR study have been extensively used by modelers at the Department of Health to inform transfusion policy to prevent the secondary spread of variant CJD.</gtr:impact><gtr:outcomeId>F178D5DD89D</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>(PPIP) National Transfusion Policy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5AE20F49-1166-47B8-A6D5-527D86357787</gtr:id><gtr:impact>The PPIP trial showed that extended shelf-life (6-7 day old) platelets are safe and do not result in decreased clinical efficacy or an immediate increase in platelet requirements compared to 2-5 day old platelets. In conjunction with the introduction of bacterial testing, it provided the evidence to support the introduction of extended shelf life platelets within the UK, which in turn has led to reduced platelet wastage.</gtr:impact><gtr:outcomeId>5458e596bcee19.48788737</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>(TOPPS) National Transfusion Policy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10F7E3FD-5053-4284-B766-7D8BE35EA765</gtr:id><gtr:impact>The TOPPS trial has demonstrated the overall benefits of continuing to give prophylactic platelets transfusions to blood cancer patients with thrombocytopaenia to reduce the rate of clinically significant bleeding as opposed to &amp;quot;therapeutic-only&amp;quot; platelet transfusions. The results also showed that there is still a high burden of bleeding in many of these patients despite being given prophylactic platelets suggesting that alternative strategies to prevent bleeding should be investigated.</gtr:impact><gtr:outcomeId>5458e539c63fa7.78916705</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>(TAPS) British Committee for Standards in Haematology guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>British Committee for Standards in Haematology guidelines for transfusion in haemoglobinopathy</gtr:guidelineTitle><gtr:id>DED11F99-172E-438F-854D-282C1B6A4309</gtr:id><gtr:impact>The TAPS trial in adults and children demonstrated that pre-operative transfusions should be offered to sickle cell patients (Hb SS) before undergoing low or medium risk surgery and these results have attracted world -wide interest. Before the trial started clinicians were equally divided in opinion as to whether they should transfuse these patients or not before low or medium risk, and increasingly many low risk patients were not being transfused.

The trial results are influencing current practice, and will benefit sickle cell patients given a pre-operative transfusions who will have a reduced chance of developing acute chest syndrome - a serious post-operative complication.</gtr:impact><gtr:outcomeId>kofspebk62q</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.bcshguidelines.com/4_HAEMATOLOGY_GUIDELINES.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>(GIN) Component Introduction</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the Blood Transfusion Services (8th Edition)</gtr:guidelineTitle><gtr:id>9C64B048-43B6-4945-BC15-14D72CC28607</gtr:id><gtr:impact>The Granulocytes in Neutropenia (GIN) Trial, was an observational study in adults and children receiving the new pooled, whole-blood derived granulocytes in additive solution and plasma component developed by the NHSBT components Laboratory. Results showed that these had a similar safety profile to existing buffy coat sources of granulocytes in neutropenic patients. This led to NHSBT offering pooled granulocytes as a routine component which has the advantages of lower volume, reduced red cell &amp;amp; plasma contamination, and resuspension in male plasma and additive solution to reduce the risk of TRALI, a serious side-effect of transfusion.</gtr:impact><gtr:outcomeId>5458dfeab4ae56.73403441</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.transfusionguidelines.org.uk/red-book</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>(PRISM-A) Advisory Committee on the Safety of Blood, Tissues and Organs recommendation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1FC30907-C756-459F-B456-321320CBF1D2</gtr:id><gtr:impact>The PRISM-A safety study demonstrated that transfusion of prion-filtered red cells to surgical patients did not increase the rate of alloimmunisation or transfusion reactions. The study report was accepted by the Department of Health safety committee (SaBTO).

PRISM-A results were used by SaBTO in reaching final recommendation on implementation of the P-Capt prion filter to help prevent the spread of vCJD.</gtr:impact><gtr:outcomeId>XaoQyaGp7oo</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Optimisation of platelet donations. Evaluation of clinical outcomes in haemato-oncology patients given platelets from donors whose platelets are at the extreme end of normal activity (e.g. hypo vs hyper reactive when their function is tested in vitro by assessing their responsiveness to 4 different types of platelet agonists).</gtr:description><gtr:id>8FF24D0F-AD9E-46B4-B404-02CEBAE3EB08</gtr:id><gtr:impact>Awaited</gtr:impact><gtr:outcomeId>DL7gNipAxFw</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PROMPT</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:ukcrnIsctnId>ISRCTN56366401</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN56366401</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies 
- Published 
- Funding: NHSBT</gtr:description><gtr:id>1DEA1FC2-E811-4B34-B320-38B76E9FF52A</gtr:id><gtr:impact>A strategy of no prophylactic platelet transfusions led to an increased rate of bleeding events of WHO grade 2, 3, or 4, with a significant increase in the number of days with bleeding events of WHO grade 2, 3, or 4. The majority of the bleeding episodes were WHO grade 2.</gtr:impact><gtr:outcomeId>LqTMRjNyHwh</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>TOPPS</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>BS02/4/RB31 
Study hypothesis The trial aims to investigate whether the administration of a blood transfusion preoperatively to patients with sickle cell disease (Hb SS or Hb SB thal) increases or decreases the overall rate of peri-operative complications.
- Published
- Funding: NHSBT</gtr:description><gtr:id>A7021A53-333B-4ED5-B665-0338FE6CCED9</gtr:id><gtr:impact>Preoperative transfusion was associated with decreased perioperative complications in patients with
sickle-cell disease in this trial. This approach could, therefore, be beneficial for patients with the haemoglobin SS
subtype who are scheduled to undergo low-risk and medium-risk surgery.</gtr:impact><gtr:outcomeId>oyktvcxLegW</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>TAPS</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Comparing 6-7day old platelets to 2-5day old platelets
- Submitted for publication
- Funding from NHSBT</gtr:description><gtr:id>3949A1B3-2F78-45A0-803B-B5EF134B342C</gtr:id><gtr:impact>Extending the shelf-life for platelets to 6-7days will increase product availability, reduce platelet wastage and improve the logistics of supply of platelets to patients.</gtr:impact><gtr:outcomeId>rvp4jymNFPP</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PPIP</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Feasibility cluster-randomised trial of two different red cell transfusion policies for the management of patients admitted with acute upper intestinal bleeding - a major users of red blood cells supplied by NHSBT.</gtr:description><gtr:id>F6C4B53B-64EC-41F1-BB37-917188F9889B</gtr:id><gtr:impact>Awaited</gtr:impact><gtr:outcomeId>C8rzhXqB3aM</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>TRIGGER</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN85757829</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Database of a representative sample of recipients of red cell, platelet and fresh frozen plasma transfusions supplied by the National Blood Service in 2001-02. Information on demography, clinical indications and survival is recorded.</gtr:description><gtr:id>CB7592AC-A839-4FE5-89B3-5827512AA28B</gtr:id><gtr:impact>Information not previously available to the National Blood Service, Department of Health and the Advisory Committee on the Safety of Blood, Tissues and Organs</gtr:impact><gtr:outcomeId>5458ddfbdfd836.03029124</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>EASTR</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Database of a representative sample of recipients of red cell, platelet and fresh frozen plasma transfusions supplied by the National Blood Service in 2001-02. Information on demography, clinical indications and survival is recorded.</gtr:description><gtr:id>198600D8-9A20-467C-A0C1-78B536701956</gtr:id><gtr:impact>Information not previously available to the National Blood Service, Department of Health and the Advisory Committee on the Safety of Blood, Tissues and Organs</gtr:impact><gtr:outcomeId>5DA4752E95B</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>EASTR</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Tool to standardise the assessment of the frequency and severity of bleeding that can be used as an outcome for the comparison of treatments for patients with bleeding disorders.</gtr:description><gtr:id>2E37CB9E-50A0-4970-AD15-FBD4CCDC7AD2</gtr:id><gtr:impact>Other groups have adopted the tool for use in their clinical research</gtr:impact><gtr:outcomeId>795880DD51D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>(TOPPS) Standardised method for assessment of bleeding</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6729201B-76A2-4BB9-B823-89E365963207</gtr:id><gtr:title>The EASTR study: a new approach to determine the reasons for transfusion in epidemiological studies.</gtr:title><gtr:parentPublicationTitle>Transfusion medicine (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a524a44e2681f48944a04b664c2d532c"><gtr:id>a524a44e2681f48944a04b664c2d532c</gtr:id><gtr:otherNames>Llewelyn CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0958-7578</gtr:issn><gtr:outcomeId>F3257708004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F1ADBA6-5B31-4E87-8C68-927300897E03</gtr:id><gtr:title>The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6faab6356a91151413bf2b8f0ea17018"><gtr:id>6faab6356a91151413bf2b8f0ea17018</gtr:id><gtr:otherNames>Howard J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_15435_25_23352054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0F8B6A5-2006-44EB-92E2-3D1EA58792FF</gtr:id><gtr:title>Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56cb0e714b7b94.09643175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C8F0820-B6D8-425E-89AA-61414DEC88AB</gtr:id><gtr:title>Prevention of bedside errors in transfusion medicine (PROBE-TM) study: a cluster-randomized, matched-paired clinical areas trial of a simple intervention to reduce errors in the pretransfusion bedside check.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/830fc98245a01f403345102615ab7181"><gtr:id>830fc98245a01f403345102615ab7181</gtr:id><gtr:otherNames>Murphy MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>217FB5FA3C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BFCE183-3591-4D6C-85EE-6B408DE427A3</gtr:id><gtr:title>Prevalence of maternal anaemia and its predictors: a multi-centre study.</gtr:title><gtr:parentPublicationTitle>European journal of obstetrics, gynecology, and reproductive biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18d59f9453b164cf9af5293f45335f8"><gtr:id>f18d59f9453b164cf9af5293f45335f8</gtr:id><gtr:otherNames>Barroso F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0301-2115</gtr:issn><gtr:outcomeId>tiVUGqZWrgf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23C24BA1-413D-4436-835B-050CA5C6D112</gtr:id><gtr:title>Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial.</gtr:title><gtr:parentPublicationTitle>Transfusion medicine reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-7963</gtr:issn><gtr:outcomeId>pm_15435_25_23706959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFD011B3-4B49-4B52-8781-96E97F61C7D7</gtr:id><gtr:title>Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>pm_15435_25_22897615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E27200DD-91F9-406F-B04B-9B85A35683A3</gtr:id><gtr:title>Reappraising the concept of massive transfusion in trauma.</gtr:title><gtr:parentPublicationTitle>Critical care (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf281493c146a7f1e52edc1c3dcabcd"><gtr:id>fcf281493c146a7f1e52edc1c3dcabcd</gtr:id><gtr:otherNames>Stanworth SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1364-8535</gtr:issn><gtr:outcomeId>Tiv8pyTCNfB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BEE3390-ACB2-4489-A803-704BDE52A75B</gtr:id><gtr:title>Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit.</gtr:title><gtr:parentPublicationTitle>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1590-8658</gtr:issn><gtr:outcomeId>56cb0e71eb7301.15634675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34F54089-391A-410E-B069-F4FCB5F4CDC1</gtr:id><gtr:title>Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf281493c146a7f1e52edc1c3dcabcd"><gtr:id>fcf281493c146a7f1e52edc1c3dcabcd</gtr:id><gtr:otherNames>Stanworth SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>545b6258b1d601.38076501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8520C2C3-1109-453E-A95D-7399FE35384A</gtr:id><gtr:title>Poor outcomes in hospitalized patients with gastrointestinal bleeding: impact of baseline risk, bleeding severity, and process of care.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>56cc3c3f640d31.84368407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8B1821F-0159-4C91-AD62-A64C9C15CABA</gtr:id><gtr:title>Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty.</gtr:title><gtr:parentPublicationTitle>Vox sanguinis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a3d9b49097d49435c55b1286408b891"><gtr:id>3a3d9b49097d49435c55b1286408b891</gtr:id><gtr:otherNames>Grover M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0042-9007</gtr:issn><gtr:outcomeId>3F682382C5B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B16FC09-CEF5-4261-BA4E-56FA2470A1C2</gtr:id><gtr:title>Nurses' role in platelet transfusion clinical trials.</gtr:title><gtr:parentPublicationTitle>Nursing times</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a4a903d1fdc5a664192f2eff6b7e494"><gtr:id>5a4a903d1fdc5a664192f2eff6b7e494</gtr:id><gtr:otherNames>Powter G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-7762</gtr:issn><gtr:outcomeId>56cc3c3f1d2be3.67825971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F05F093-1C1B-44B9-BBAB-661121D25C77</gtr:id><gtr:title>Prospective, observational study of outcomes in neonates with severe thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf281493c146a7f1e52edc1c3dcabcd"><gtr:id>fcf281493c146a7f1e52edc1c3dcabcd</gtr:id><gtr:otherNames>Stanworth SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>2A75EFAB754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A61DC5E7-0619-4D76-B5BF-CCCA20F63BCB</gtr:id><gtr:title>Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding.</gtr:title><gtr:parentPublicationTitle>Vox sanguinis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf281493c146a7f1e52edc1c3dcabcd"><gtr:id>fcf281493c146a7f1e52edc1c3dcabcd</gtr:id><gtr:otherNames>Stanworth SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0042-9007</gtr:issn><gtr:outcomeId>931E3C674A2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC39BAE4-32B3-45B3-8CB8-18BDD4D61E26</gtr:id><gtr:title>The granulocytes in neutropenia 1 (GIN 1) study: a safety study of granulocytes collected from whole blood and stored in additive solution and plasma.</gtr:title><gtr:parentPublicationTitle>Transfusion medicine (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d30e9b08175bb3718e71aebe740895bd"><gtr:id>d30e9b08175bb3718e71aebe740895bd</gtr:id><gtr:otherNames>Massey E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0958-7578</gtr:issn><gtr:outcomeId>pm_15435_25_22591484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A81E5ACF-E641-4D50-BDAD-4643D101CD81</gtr:id><gtr:title>Electronic remote blood issue: a combination of remote blood issue with a system for end-to-end electronic control of transfusion to provide a &amp;quot;total solution&amp;quot; for a safe and timely hospital blood transfusion service.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/171ce85d0e7196308a8603512a437bf8"><gtr:id>171ce85d0e7196308a8603512a437bf8</gtr:id><gtr:otherNames>Staves J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>j6AKCyAq9sy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E06AF3D-63E3-4031-B59F-0131E14DFBA3</gtr:id><gtr:title>Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial.</gtr:title><gtr:parentPublicationTitle>European journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40da9a8542989d6ad16653b581647b3b"><gtr:id>40da9a8542989d6ad16653b581647b3b</gtr:id><gtr:otherNames>Spackman E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0902-4441</gtr:issn><gtr:outcomeId>5458bc7715faa4.27568628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82B7BDA4-A20F-4FC1-841B-5A9A30A0887D</gtr:id><gtr:title>Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_15435_25_23837630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A77D4EF-2756-4FB9-95B8-B1D4A574364E</gtr:id><gtr:title>Mortality from acute upper gastrointestinal bleeding in the United kingdom: does it display a &amp;quot;weekend effect&amp;quot;?</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>FnCJSZK831D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F18A0F1E-D3C0-4B8B-9D9C-8DA715528107</gtr:id><gtr:title>Severe thrombocytopenia and patterns of bleeding in neonates: results from a prospective observational study and implications for use of platelet transfusions.</gtr:title><gtr:parentPublicationTitle>Transfusion medicine (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9293dbed6a7fab86a8e0466bc774d92d"><gtr:id>9293dbed6a7fab86a8e0466bc774d92d</gtr:id><gtr:otherNames>Muthukumar P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0958-7578</gtr:issn><gtr:outcomeId>pm_15435_25_22738179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FA9DCB5-D0E0-4114-8E91-B559E3FB6BC2</gtr:id><gtr:title>The EASTR Study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service.</gtr:title><gtr:parentPublicationTitle>Transfusion medicine (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c09fba0730f153d8f23eb7de367878b6"><gtr:id>c09fba0730f153d8f23eb7de367878b6</gtr:id><gtr:otherNames>Wells AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0958-7578</gtr:issn><gtr:outcomeId>F7CC2E433C2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A64A50BC-5FE7-47EA-BF0C-70A26CB6BB8D</gtr:id><gtr:title>Platelets for neonatal transfusion - study 2: a randomised controlled trial to compare two different platelet count thresholds for prophylactic platelet transfusion to preterm neonates.</gtr:title><gtr:parentPublicationTitle>Neonatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ceaa199c71c05f91b4963219ecba7ef"><gtr:id>7ceaa199c71c05f91b4963219ecba7ef</gtr:id><gtr:otherNames>Curley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1661-7800</gtr:issn><gtr:outcomeId>545b6259132666.54284258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EF025FE-09E2-4C48-A25A-8937EED0BBC0</gtr:id><gtr:title>Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/548fa19215498d9c85b05fd91150f39e"><gtr:id>548fa19215498d9c85b05fd91150f39e</gtr:id><gtr:otherNames>Chapman CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>pm_15435_15_18980623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5685289-8310-4D96-91FF-FDEB814DD3D0</gtr:id><gtr:title>A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef10e2fc0d09f68bd9fed1aa09dc9d09"><gtr:id>ef10e2fc0d09f68bd9fed1aa09dc9d09</gtr:id><gtr:otherNames>MacLennan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>56cb0e71af1254.66941558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A61385BE-0268-4691-BE2D-F0A9E1581941</gtr:id><gtr:title>Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study.</gtr:title><gtr:parentPublicationTitle>Endoscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0013-726X</gtr:issn><gtr:outcomeId>pm_15435_25_22752889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B8C8D53-4849-48D4-94D9-63688EDEB01C</gtr:id><gtr:title>Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fa4113ade3f41c36ba5838296108ff"><gtr:id>03fa4113ade3f41c36ba5838296108ff</gtr:id><gtr:otherNames>Campbell HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>56cb0e71815b27.70962671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C5B4A68-3272-4D6F-845B-9BC4D37A43B9</gtr:id><gtr:title>A no-prophylaxis platelet-transfusion strategy for hematologic cancers.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf281493c146a7f1e52edc1c3dcabcd"><gtr:id>fcf281493c146a7f1e52edc1c3dcabcd</gtr:id><gtr:otherNames>Stanworth SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15435_25_23656642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B063B73B-F1AB-49B3-835E-D09A26EF5BB0</gtr:id><gtr:title>Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.</gtr:title><gtr:parentPublicationTitle>Transfusion medicine reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf281493c146a7f1e52edc1c3dcabcd"><gtr:id>fcf281493c146a7f1e52edc1c3dcabcd</gtr:id><gtr:otherNames>Stanworth SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-7963</gtr:issn><gtr:outcomeId>LJrf8KxT1kJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B199957-FFD6-4B63-8B48-D6814B26FF4E</gtr:id><gtr:title>Transfusion of prion-filtered red cells does not increase the rate of alloimmunization or transfusion reactions in patients: results of the UK trial of prion-filtered versus standard red cells in surgical patients (PRISM A).</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5b44f4e5b8390c962297e639fc5af62"><gtr:id>d5b44f4e5b8390c962297e639fc5af62</gtr:id><gtr:otherNames>Elebute MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_15435_25_23294293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4161C73C-9206-4C32-BDA4-32B0ABBE566E</gtr:id><gtr:title>Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fa4113ade3f41c36ba5838296108ff"><gtr:id>03fa4113ade3f41c36ba5838296108ff</gtr:id><gtr:otherNames>Campbell HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>545b6258dc63c2.57703428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2375EE51-4AA6-4520-A19D-03AB72454165</gtr:id><gtr:title>National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>pm_15435_25_23023268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E846EBA-F9F6-475D-A507-26785D36A64F</gtr:id><gtr:title>A novel approach to standardised recording of bleeding in a high risk neonatal population.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood. Fetal and neonatal edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84743cd573b2d09f9cf1a56b00f4fab8"><gtr:id>84743cd573b2d09f9cf1a56b00f4fab8</gtr:id><gtr:otherNames>Venkatesh V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-2998</gtr:issn><gtr:outcomeId>56cc3c3ee466b0.85115833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>973478F7-0FFF-4D05-9E9D-929831A93B67</gtr:id><gtr:title>The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>54d33d3ff25297.66083685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81CCE237-828D-4674-A763-DF7B54A0E547</gtr:id><gtr:title>Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71bf133c98889b2c6f7ac65d46f6bfcc"><gtr:id>71bf133c98889b2c6f7ac65d46f6bfcc</gtr:id><gtr:otherNames>Jairath V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>iucESMhztfM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F76BF93-279D-4E89-8399-56C4F5ACEFBA</gtr:id><gtr:title>Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>54d33d3fc053e6.45536350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB7EAFC2-3E87-4259-A12E-5C2EBF082176</gtr:id><gtr:title>End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: strengths and weaknesses.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa3532ffe1fc272856d4b64bfe31e1b0"><gtr:id>fa3532ffe1fc272856d4b64bfe31e1b0</gtr:id><gtr:otherNames>Davies A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>A904535B111</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122870183</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>